Evidence map›Paper›PMID 42050077›Full record

ArticleOncogene2026

Rapid activation of ARF6 after RAF inhibition augments BRAF

Junhua Wang, Yinshen Wee, Thomas Jacob, Aaron Rogers, Lise K Sorensen, Deja M Brooks, Prachi Gupta, Joshua K H Tay, Emily C Wilson, Tong Liu and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Junhua WangDepartment of Oncologic Sciences, University of Utah, Salt Lake City, UT, USA.ORCID http://orcid.org/0000-0003-4424-8502
Yinshen WeeDepartment of Pathology, University of Utah, Salt Lake City, UT, USA.
Thomas JacobProvidence Cancer Institute, Earle A. Chiles Research Institute, Portland, OR, USA.
Aaron RogersDepartment of Pathology, University of Utah, Salt Lake City, UT, USA.
Lise K SorensenDepartment of Pathology, University of Utah, Salt Lake City, UT, USA.
Deja M BrooksProvidence Cancer Institute, Earle A. Chiles Research Institute, Portland, OR, USA.
Prachi GuptaProvidence Cancer Institute, Earle A. Chiles Research Institute, Portland, OR, USA.
Joshua K H TayDepartment of Pathology, University of Utah, Salt Lake City, UT, USA.ORCID http://orcid.org/0009-0004-0626-8662
Emily C WilsonDepartment of Pathology, University of Utah, Salt Lake City, UT, USA.ORCID http://orcid.org/0009-0004-4037-9366
Tong LiuDepartment of Dermatology, University of Utah, Salt Lake City, UT, USA.
Eric A SmithDepartment of Pathology, University of Utah, Salt Lake City, UT, USA.ORCID http://orcid.org/0000-0002-7510-5603
Y N Vashisht GopalDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michael A DaviesDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-0977-0912
Martin McMahonDepartment of Oncologic Sciences, University of Utah, Salt Lake City, UT, USA.ORCID http://orcid.org/0000-0003-2812-1042
Sheri L HolmenDepartment of Oncologic Sciences, University of Utah, Salt Lake City, UT, USA.ORCID http://orcid.org/0000-0002-6411-6032
Robert L Judson-TorresDepartment of Oncologic Sciences, University of Utah, Salt Lake City, UT, USA.ORCID http://orcid.org/0000-0002-6559-0553
Roger K WolffDepartment of Pathology, University of Utah, Salt Lake City, UT, USA.
Allie H GrossmannDepartment of Oncologic Sciences, University of Utah, Salt Lake City, UT, USA. allie.grossmann@providence.org.ORCID http://orcid.org/0000-0002-7665-1403

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
The University of Texas MD Anderson Cancer Center SPORE in MelanomaP50CA221703 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WARGO, JENNIFER A. · 2019 to 2023
$10.3M
Efficacy of combined inhibition of BRAF, MEK, and FAK in melanoma patient derived xenograftsR01CA121118 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Sheri L Holmen · 2007 to 2026
$4.7M
Targeting Rheostatic Mechanisms of Melanoma ProgressionR37CA230630 · NCI · UNIVERSITY OF UTAH · PI Allie H. Grossmann · 2020 to 2026
$2.5M
The Role of the Small GTPase ARF6 in Oncogenic Signaling and TumorigenesisK08CA188563 · NCI · UNIVERSITY OF UTAH · PI GROSSMANN, ALLIE H. · 2015 to 2019
$902k
American Cancer Society (American Cancer Society, Inc.) 133649-RSG-19-019-01-CSMNCI NIH HHS K08 CA188563NCI NIH HHS P30 CA042014NCI NIH HHS P50 CA221703NCI NIH HHS R01 CA121118NCI NIH HHS R37 CA230630U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) K08CA188563U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R37CA230630
6 · The paper itself

Abstract

The intrinsic ability of cancer cells to evade death underpins tumorigenesis, progression, metastasis, and the survival of drug-tolerant persister (DTP) cells. Herein, we discovered that the small GTPase ARF6 plays a central role in tumor survival by fortifying RAF oncoprotein levels. ARF6 activation was sufficient to increase BRAF

Indexed as

ADP-Ribosylation FactorsDrug Resistance, NeoplasmMelanomaProto-Oncogene Proteins B-rafADP-Ribosylation Factor 6AnimalsCell Line, TumorHumansMiceProtein Kinase InhibitorsXenograft Model Antitumor AssaysADP-Ribosylation Factor 6ADP-Ribosylation FactorsARF6 protein, humanArf6 protein, mouseBRAF protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins B-raf

Identifiers

PMID42050077
PMCPMC13158949

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.